Close

Medivation (MDVN) Tops Q2 EPS by 13c

August 6, 2015 4:15 PM EDT
Get Alerts MDVN Hot Sheet
Price: $81.44 --0%

Financial Fact:
Net loss: -403.92M

Today's EPS Names:
CSHX, BGI, RVCB, More
Join SI Premium – FREE

Medivation (NASDAQ: MDVN) reported Q2 EPS of $0.58, $0.13 better than the analyst estimate of $0.45. Revenue for the quarter came in at $175.7 million versus the consensus estimate of $159.42 million.

"XTANDI's performance, in both the U.S. and outside the U.S., demonstrates continued traction toward becoming a foundation of therapy for the treatment of metastatic castration-resistant prostate cancer," said David Hung, M.D., president and chief executive officer of Medivation. "Medivation will continue to pursue innovative programs that have the potential to make a meaningful impact in the quality of life of patients with serious disease."

For earnings history and earnings-related data on Medivation (MDVN) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Management Comments

Related Entities

Earnings